Inhibition of virus attachment to CD4(+) target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

被引:110
作者
Ugolini, S
Mondor, I
Parren, PWHI
Burton, DR
Tilley, SA
Klasse, PJ
Sattentau, QJ
机构
[1] CTR IMMUNOL MARSEILLE LUMINY, F-13288 MARSEILLE 9, FRANCE
[2] SCRIPPS RES INST, LA JOLLA, CA 92037 USA
[3] PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA
[4] UNIV LONDON UNIV COLL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND
关键词
D O I
10.1084/jem.186.8.1287
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody-mediated neutralization of human immunodeficiency virus type-1 (HIV-1) is thought to function by at least two distinct mechanisms: inhibition of virus-receptor binding, and interference with events after binding, such as virus-cell membrane fusion. Here we show, by the use of a novel virus-cell binding assay, that soluble CD4 and monoclonal antibodies to all confirmed glycoprotein (gp)120 neutralizing epitopes, including the CD4 binding site and the V2 and V3 loops, inhibit the adsorption of two T cell Line-adapted HIV-I viruses to CD4(+) cells. A correlation between the inhibition of virus binding and virus neutralization was observed for soluble CD4 and all anti-gp120 antibodies, indicating that this is a major mechanism of HIV neutralization. By contrast, antibodies specific for regions of gp120 other than the CD4 binding site showed little or no inhibition of either soluble, gp120 binding to CD4(+) cells or soluble CD4 binding to HIV-infected cells, implying that this effect is specific to the virion-cell interaction. However, inhibition of HIV-1 attachment to cells is not a universal mechanism of neutralization, since an anti-gp41 antibody did not inhibit virus-cell binding at neutralizing concentrations, implying activity after virus-cell binding.
引用
收藏
页码:1287 / 1298
页数:12
相关论文
共 73 条
[1]   Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1 [J].
Armstrong, SJ ;
McInerney, TL ;
McLain, L ;
Wahren, B ;
Hinkula, J ;
Levi, M ;
Dimmock, NJ .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :2931-2941
[2]  
BAHRAOUI E, 1988, AIDS, V2, P165
[3]   RECOMBINANT HUMAN FAB FRAGMENTS NEUTRALIZE HUMAN TYPE-1 IMMUNODEFICIENCY VIRUS INVITRO [J].
BARBAS, CF ;
BJORLING, E ;
CHIODI, F ;
DUNLOP, N ;
CABABA, D ;
JONES, TM ;
ZEBEDEE, SL ;
PERSSON, MAA ;
NARA, PL ;
NORRBY, E ;
BURTON, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) :9339-9343
[4]   MOLECULAR PROFILE OF AN ANTIBODY-RESPONSE TO HIV-1 AS PROBED BY COMBINATORIAL LIBRARIES [J].
BARBAS, CF ;
COLLET, TA ;
AMBERG, W ;
ROBEN, P ;
BINLEY, JM ;
HOEKSTRA, D ;
CABABA, D ;
JONES, TM ;
WILLIAMSON, RA ;
PILKINGTON, GR ;
HAIGWOOD, NL ;
CABEZAS, E ;
SATTERTHWAIT, AC ;
SANZ, I ;
BURTON, DR .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 230 (03) :812-823
[5]   Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations [J].
Bess, JW ;
Gorelick, RJ ;
Bosche, WJ ;
Henderson, LE ;
Arthur, LO .
VIROLOGY, 1997, 230 (01) :134-144
[6]   CRYPTIC NATURE OF ENVELOPE V3 REGION EPITOPES PROTECTS PRIMARY MONOCYTOTROPIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 FROM ANTIBODY NEUTRALIZATION [J].
BOUHABIB, DC ;
RODERIQUEZ, G ;
ORAVECZ, T ;
BERMAN, PW ;
LUSSO, P ;
NORCROSS, MA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6006-6013
[7]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[8]   A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS [J].
BURTON, DR ;
BARBAS, CF ;
PERSSON, MAA ;
KOENIG, S ;
CHANOCK, RM ;
LERNER, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10134-10137
[9]  
BURTON DR, 1997, AIDS SA, V11, pS87
[10]  
CHAMAT S, 1992, J IMMUNOL, V149, P649